Skip to main content

Main menu

  • HOME
  • ARTICLES
    • Current Issue
    • Ahead of Print
    • Archives
    • Abstracts In Press
    • Special Issue Archive
    • Subject Collections
  • INFO FOR
    • Authors
    • Reviewers
    • Call For Papers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • ABOUT
    • The JABFM
    • The Editing Fellowship
    • Editorial Board
    • Indexing
    • Editors' Blog
  • CLASSIFIEDS
  • Other Publications
    • abfm

User menu

  • Log out

Search

  • Advanced search
American Board of Family Medicine
  • Other Publications
    • abfm
  • Log out
American Board of Family Medicine

American Board of Family Medicine

Advanced Search

  • HOME
  • ARTICLES
    • Current Issue
    • Ahead of Print
    • Archives
    • Abstracts In Press
    • Special Issue Archive
    • Subject Collections
  • INFO FOR
    • Authors
    • Reviewers
    • Call For Papers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • ABOUT
    • The JABFM
    • The Editing Fellowship
    • Editorial Board
    • Indexing
    • Editors' Blog
  • CLASSIFIEDS
  • JABFM on Bluesky
  • JABFM On Facebook
  • JABFM On Twitter
  • JABFM On YouTube
Brief ReportBrief Report

Urine Drug Testing Among Patients Prescribed Long-Term Opioid Therapy: Patient and Clinician Factors

Alicia L. Agnoli, Rebecca Howe, Elizabeth Magnan, Anthony Jerant, Daniel Colby and Peter Franks
The Journal of the American Board of Family Medicine August 2023, 36 (4) 537-541; DOI: https://doi.org/10.3122/jabfm.2022.220360R1
Alicia L. Agnoli
From the Department of Family & Community Medicine, UC Davis (AA); Department of Family & Community Medicine, UC Davis (RH, EM, AJ, PF); Department of Emergency Medicine, UC Davis (DC).
MD, MPH, MHS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rebecca Howe
From the Department of Family & Community Medicine, UC Davis (AA); Department of Family & Community Medicine, UC Davis (RH, EM, AJ, PF); Department of Emergency Medicine, UC Davis (DC).
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth Magnan
From the Department of Family & Community Medicine, UC Davis (AA); Department of Family & Community Medicine, UC Davis (RH, EM, AJ, PF); Department of Emergency Medicine, UC Davis (DC).
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony Jerant
From the Department of Family & Community Medicine, UC Davis (AA); Department of Family & Community Medicine, UC Davis (RH, EM, AJ, PF); Department of Emergency Medicine, UC Davis (DC).
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Colby
From the Department of Family & Community Medicine, UC Davis (AA); Department of Family & Community Medicine, UC Davis (RH, EM, AJ, PF); Department of Emergency Medicine, UC Davis (DC).
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Franks
From the Department of Family & Community Medicine, UC Davis (AA); Department of Family & Community Medicine, UC Davis (RH, EM, AJ, PF); Department of Emergency Medicine, UC Davis (DC).
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
Loading

Abstract

Introduction: National guidelines recommend that patients with chronic noncancer pain prescribed long-term opioid therapy (LTOT) undergo periodic urine drug testing (UDT), yet UDT is performed inconsistently, and little evidence supports the utility of this approach. We examined patient and prescriber factors associated with UDT.

Methods: A 1-year retrospective cohort study of 5690 patients prescribed LTOT by 689 clinicians in a network of 13 primary care and specialty clinics. Negative binomial regression examined patient and prescriber factors associated with the number of tests completed, and logistic regression examined prescriber and practice level testing likelihood. Analyses were adjusted for patient and clinician characteristics and accounted for patient clustering within prescribers.

Results: A total of 2256 patients (39.6%) had UDT completed at least once. More UDT completion was associated with Black patient race and receipt of more opioid prescriptions, as well as with clinician testing compliance.

Conclusions: UDT was relatively infrequent in patients prescribed LTOT and associated with patient factors not known to confer greater opioid-related risk, such as race. In addition, there was significant clinician-driven variation in UDT. Given the uncertain clinical utility of such testing, these findings signal the need for strategies to address potential biases in the use of UDT.

  • Chronic Pain
  • Logistic Regression
  • Medical Decision-Making
  • Opioids
  • Physician-Patient Relations
  • Retrospective Studies
  • Substance Abuse Testing
  • Urine Collection

Introduction

Recent guidelines intended to increase the safety of prescribing of opioids for chronic noncancer pain include recommendations for routine urine drug testing (UDT).1,2 Such testing is proposed to offer an indication of appropriate medication use and potential misuse, and is now commonly considered as a quality of care metric for patients on long-term opioid therapy (LTOT).1⇓–3 However, evidence to support the clinical utility of UDT in monitoring patients on LTOT is lacking.3⇓–5

Testing based on perceived aberrant behaviors alone has been shown to be ineffective, prone to clinician biases, and can result in decision making based on stereotypes.6⇓–8 Routine periodic screening for potential opioid misuse—where patients on LTOT undergo UDT 1 to 3 or more times per year—is now recommended in national care guidelines with the aim of providing standardized and more equitable monitoring.3 However, wide variability remains in the application of UDT, with inconsistencies in which patients are targeted for testing and how test results are interpreted by clinicians.6,7

The variation in UDT practice can result in disparate outcomes among patients prescribed LTOT.8 Prior work found that Black patients are more likely than white patients to have UDT, despite evidence suggesting white males are more likely to misuse opioids.9 In addition, clinicians are more likely to discontinue LTOT for Black patients compared with white patients when UDT is positive for an illicit drug.10 Recognizing that testing is poorly standardized among clinicians,10 we sought to better understand the factors contributing to this variability by examining UDT in patients prescribed LTOT in a network of primary care and ambulatory specialty care offices.

Methods

This retrospective cohort study examined the electronic health records for 5690 patients without cancer prescribed LTOT between January 1, 2018, and December 31, 2018, across a large network of primary care offices and specialty clinics affiliated within an academic health system in Northern California. Patients were included if they received 3 or more opioid prescriptions in any 90-day window, which is consistent with health system criteria for inclusion in an opioid therapy monitoring program for LTOT with recommendation for at least annual UDT. These patients would have a flagged “care gap” in their electronic chart for UDT, visible to all opioid prescribers in the health system. The University of California IRB determined this study was exempt from review.

Outcome

The outcomes of interest were patient completion of any UDT within the study year (yes/no) and number of UDT.

Covariates

We controlled for key patient factors including age, sex, self-reported race/ethnicity (white, Black, Asian, other), insurance (Medicaid or not), English language preferred (or not), number of opioid prescriptions in the study year, maximum daily average dose of prescribed opioids (MME, morphine milliequivalents) in the study year, and number of office visits in the study year. We also included available prescriber factors: Prescriber sex (male/female) and specialty type (Family Medicine, Internal Medicine, other specialty).

Statistical Analysis

Mixed models accounted for nesting of patients within prescribers as well as clinics. Negative binomial regression estimated the adjusted association between patient and prescriber factors and the number of tests patients completed during the study period. Logistic regression examined the adjusted prescriber and clinic intraclass correlation (rho) to account for clinician and practice testing likelihood, respectively. All analyses were performed using Stata version 16.1 (StataCorp, College Station, TX).

Results

Our sample included 5690 patients prescribed at least 3 months of opioid therapy during the study period, of which 2216 completed at least 1 urine drug test. These patients were distributed over 689 prescribing clinicians, with each prescriber having approximately 8 patients in the sample (mean = 8.3 patients, range 1 to 147).

Unadjusted results revealed that, compared with patients who had no UDT during the study period, patients who had at least 1 test were disproportionately Black, less likely to be Asian, more likely to be age 30 to 49 or 50 to 64, not insured by Medicaid, and English-speaking. They had more opioid prescriptions and higher average opioid doses (MME). They were also more commonly seen by female and Internal Medicine prescribers (Table 1).

View this table:
  • View inline
  • View popup
Table 1.

Characteristics of Patients Prescribed Long-Term Opioid Therapy, by Urine Drug Testing Status

The negative binomial regression analysis revealed few adjusted patient-level factors significantly associated with testing: Black patients (vs white) had a higher rate of testing, whereas Asian patients (vs white) had a lower rate of testing. More testing was also associated with a higher number of opioid prescriptions. Other patient factors, including number of office visits and maximum daily dose, were not significantly associated with testing (Table 2).

View this table:
  • View inline
  • View popup
Table 2.

Adjusted Association of Urine Drug Testing by Patient and Prescriber Factors

Patients of internists, as compared with Family Physicians, were more likely to be tested, whereas patients prescribed opioids by other specialists were less likely to be tested. Patients of female prescribers (compared with male) were more likely to be tested (Table 2). There was significant intraclass correlation (ICC) by prescriber (rho = 0.27, 95% confidence interval [CI]= 0.20–0.35); clinic ICC was also significant (rho = 0.13, [95% CI = 0.06–0.24]).

Conclusions

Our analyses of patients prescribed long-term opioids for chronic pain suggest that urine drug testing is utilized inconsistently and scarcely based on use guidelines. Heterogeneity in urine drug testing within this sample population showed that certain patient factors were associated with testing. However, only the number of opioid prescriptions (an indication of duration of therapy) is plausibly connected with reason and opportunity for testing.

Prescriber factors were also associated with urine drug testing, with both sex and specialty being significantly correlated. The significant intraclass correlation in the fully adjusted multilevel model indicated that a patient’s likelihood of being tested is associated with their prescriber’s tendency to be in compliance with recommended testing. The clinician-level associations are notable given these data derive from a single health system with standardized practice guidelines at the time of the study. These findings highlight the marked variability in application of UDT, consistent with uncertain evidence of benefit.11

In interpreting these results, we acknowledge key limitations. The data are from 1 year in a single health system and may not generalize to other care settings. Our cohort included all patients who met LTOT criteria during the study and may include some patients who were discontinued from therapy (and no longer indicated to have UDT). We measured completed (resulted) UDT at any time during the study year, but we were unable to determine if the test was ordered by the opioid prescriber or account for tests ordered and not completed.

These findings are consistent with those of other studies showing that urine drug testing in long-term opioid therapy is inconsistent with guidelines and that great variability exists in how the testing is applied, notably influenced by differences in clinician practice. Updated guidelines from the Centers for Disease Control and Prevention have modified the recommendation for UDT, advising clinicians to “consider the risks and benefits of toxicology testing,” (category B) and acknowledging a lack of evidence of effectiveness of drug testing in LTOT risk mitigation.12 Nevertheless, most health systems, professional societies, and other clinical guidelines continue to emphasize the role of UDT in opioid therapy.3,13,14 Testing in this study was driven at least in part by patient characteristics that are not associated with opioid-related risk, such as race. If regular drug testing continues to be recommended for patients prescribed LTOT, strategies must be developed to minimize the potential for bias in its application.

Notes

  • This article was externally peer reviewed.

  • Funding: This work was partially supported by a grant from the UC Davis Clinical and Translational Science Center (CTSC) Pilot Program (supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through grant number UL1 TR001860).

  • Conflict of interest: None.

  • To see this article online, please go to: http://jabfm.org/content/36/4/537.full.

  • Received for publication October 19, 2022.
  • Revision received December 30, 2022.
  • Accepted for publication January 3, 2023.

References

  1. 1.↵
    1. Dowell D,
    2. Haegerich TM,
    3. Chou R
    . CDC guideline for prescribing opioids for chronic pain—United States, 2016. Jama 2016;315:1624–45.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Manchikanti L,
    2. Kaye A,
    3. Knezevic NN,
    4. et al
    . Responsible, safe, and effective prescription of opioids for chronic non-cancer pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines. Pain Physician 2017;20:S3–S92.
    OpenUrlPubMed
  3. 3.↵
    1. Argoff CE,
    2. Alford DP,
    3. Fudin J,
    4. et al
    . Rational urine drug monitoring in patients receiving opioids for chronic pain: consensus recommendations. Pain Med 2018;19:97–117.
    OpenUrl
  4. 4.↵
    1. Turner JA,
    2. Saunders K,
    3. Shortreed SM,
    4. et al
    . Chronic opioid therapy risk reduction initiative: impact on urine drug testing rates and results. J Gen Intern Med 2014;29:305–11.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Larochelle MR,
    2. Cruz R,
    3. Kosakowski S,
    4. et al
    . Do urine drug tests reveal substance misuse among patients prescribed opioids for chronic pain? J Gen Intern Med 2022;37:2365–72. Epub 2021 Aug 17.
    OpenUrl
  6. 6.↵
    1. Sherman KJ,
    2. Walker RL,
    3. Saunders K,
    4. et al
    . Doctor-patient trust among chronic pain patients on chronic opioid therapy after opioid risk reduction initiatives: a survey. J Am Board Fam Med 2018;31:578–87.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Katz NP,
    2. Sherburne S,
    3. Beach M,
    4. et al
    . Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesth Analg 2003;97:1097–102.
    OpenUrlPubMed
  8. 8.↵
    1. Becker WC,
    2. Starrels JL,
    3. Heo M,
    4. et al
    . Racial differences in primary care opioid risk reduction strategies. Ann Fam Med 2011;9:219–25.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Gaither JR,
    2. Gordon K,
    3. Crystal S,
    4. et al
    . Racial disparities in discontinuation of long-term opioid therapy following illicit drug use among black and white patients. Drug Alcohol Depend 2018;192:371–6.
    OpenUrlPubMed
  10. 10.↵
    1. Chua I,
    2. Petrides AK,
    3. Schiff GD,
    4. et al
    . Provider misinterpretation, documentation, and follow-up of definitive urine drug testing results. J Gen Intern Med 2020;35:283–90.
    OpenUrl
  11. 11.↵
    1. Eddy DM
    . Variations in physician practice: the role of uncertainty. Health Aff (Millwood) 1984;3:74–89.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Dowell D,
    2. Ragan KR,
    3. Jones CM,
    4. et al
    . CDC clinical practice guideline for prescribing opioids for pain—United States, 2022. MMWR Recomm Rep 2022;71:1–95.
    OpenUrl
  13. 13.↵
    VA/DoD Clinical Practice Guideline. (2022). Use of Opioids in the Management of Chronic Pain Work Group. Washington, DC: U.S. Government Printing Office.
  14. 14.↵
    NIDA. Improving opioid prescribing. National Institute on Drug Abuse. Available from: https://nida.nih.gov/publications/improving-opioid-prescribing. March 30, 2017. Accessed December 19, 2022.
PreviousNext
Back to top

In this issue

The Journal of the American Board of Family     Medicine: 36 (4)
The Journal of the American Board of Family Medicine
Vol. 36, Issue 4
July-August 2023
  • Table of Contents
  • Table of Contents (PDF)
  • Cover (PDF)
  • Index by author
  • Back Matter (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on American Board of Family Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Urine Drug Testing Among Patients Prescribed Long-Term Opioid Therapy: Patient and Clinician Factors
(Your Name) has sent you a message from American Board of Family Medicine
(Your Name) thought you would like to see the American Board of Family Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 10 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Urine Drug Testing Among Patients Prescribed Long-Term Opioid Therapy: Patient and Clinician Factors
Alicia L. Agnoli, Rebecca Howe, Elizabeth Magnan, Anthony Jerant, Daniel Colby, Peter Franks
The Journal of the American Board of Family Medicine Aug 2023, 36 (4) 537-541; DOI: 10.3122/jabfm.2022.220360R1

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Urine Drug Testing Among Patients Prescribed Long-Term Opioid Therapy: Patient and Clinician Factors
Alicia L. Agnoli, Rebecca Howe, Elizabeth Magnan, Anthony Jerant, Daniel Colby, Peter Franks
The Journal of the American Board of Family Medicine Aug 2023, 36 (4) 537-541; DOI: 10.3122/jabfm.2022.220360R1
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Methods
    • Results
    • Conclusions
    • Notes
    • References
  • Figures & Data
  • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Thinking and Practicing Thoughtfully and Thoroughly
  • Google Scholar

More in this TOC Section

  • Association of Social Needs with Diabetes Outcomes in an Older Population
  • Insurance Instability Among Community-Based Health Center Patients with Diabetes Post-Affordable Care Act Medicaid Expansion
  • Factors Influencing Changing Scopes of Practice Among Contemporary Graduates of the Nation’s Largest Family Medicine Residency
Show more Brief Report

Similar Articles

Keywords

  • Chronic Pain
  • Logistic Regression
  • Medical Decision-Making
  • Opioids
  • Physician-Patient Relations
  • Retrospective Studies
  • Substance Abuse Testing
  • Urine Collection

Navigate

  • Home
  • Current Issue
  • Past Issues

Authors & Reviewers

  • Info For Authors
  • Info For Reviewers
  • Submit A Manuscript/Review

Other Services

  • Get Email Alerts
  • Classifieds
  • Reprints and Permissions

Other Resources

  • Forms
  • Contact Us
  • ABFM News

© 2025 American Board of Family Medicine

Powered by HighWire